These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 11721685)
1. Increased risk of leukemia relapse with high dose cyclosporine after allogeneic marrow transplantation for acute leukemia: 10 year follow-up of a randomized study. Bicigalupo A; Lamparelli T; Gualandi F; Bregante S; Raiola A; di Grazia C; Dominietto A; Romagnani C; Occhini D; Frassoni F; van Lint MT Blood; 2001 Nov; 98(10):3174-5. PubMed ID: 11721685 [No Abstract] [Full Text] [Related]
2. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. Locatelli F; Zecca M; Rondelli R; Bonetti F; Dini G; Prete A; Messina C; Uderzo C; Ripaldi M; Porta F; Giorgiani G; Giraldi E; Pession A Blood; 2000 Mar; 95(5):1572-9. PubMed ID: 10688810 [TBL] [Abstract][Full Text] [Related]
3. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Ratanatharathorn V; Nash RA; Przepiorka D; Devine SM; Klein JL; Weisdorf D; Fay JW; Nademanee A; Antin JH; Christiansen NP; van der Jagt R; Herzig RH; Litzow MR; Wolff SN; Longo WL; Petersen FB; Karanes C; Avalos B; Storb R; Buell DN; Maher RM; Fitzsimmons WE; Wingard JR Blood; 1998 Oct; 92(7):2303-14. PubMed ID: 9746768 [TBL] [Abstract][Full Text] [Related]
4. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Hiraoka A; Ohashi Y; Okamoto S; Moriyama Y; Nagao T; Kodera Y; Kanamaru A; Dohy H; Masaoka T; Bone Marrow Transplant; 2001 Jul; 28(2):181-5. PubMed ID: 11509936 [TBL] [Abstract][Full Text] [Related]
5. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465 [TBL] [Abstract][Full Text] [Related]
6. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Ringdén O; Labopin M; Gluckman E; Reiffers J; Vernant JP; Jouet JP; Harrousseau JL; Fiere D; Bacigalupo A; Frassoni F; Gorin NC Bone Marrow Transplant; 1996 Nov; 18(5):921-9. PubMed ID: 8932846 [TBL] [Abstract][Full Text] [Related]
7. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival. Ross M; Schmidt GM; Niland JC; Amylon MD; Dagis AC; Long GD; Nademanee AP; Negrin RS; O'Donnell MR; Parker PM; Smith EP; Snyder DS; Stein AS; Wong RM; Forman SJ; Blume KG; Chao NJ Biol Blood Marrow Transplant; 1999; 5(5):285-91. PubMed ID: 10534058 [TBL] [Abstract][Full Text] [Related]
8. [The use of allogeneic bone marrow transplantation and immunosuppressive therapy in the treatment of patients with acquired aplastic anemia]. Ganapiev AA; Golubovskaia IK; Zalialov IuR; Estrina MA; Afanas'ev BV Ter Arkh; 2010; 82(7):48-52. PubMed ID: 20853609 [TBL] [Abstract][Full Text] [Related]
9. The combined effect of total body irradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation. Bacigalupo A; Vitale V; Corvò R; Barra S; Lamparelli T; Gualandi F; Mordini N; Berisso G; Bregante S; Raiola AM; Van Lint MT; Frassoni F Br J Haematol; 2000 Jan; 108(1):99-104. PubMed ID: 10651732 [TBL] [Abstract][Full Text] [Related]
10. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Wagner JE; Thompson JS; Carter SL; Kernan NA; Lancet; 2005 Aug 27-Sep 2; 366(9487):733-41. PubMed ID: 16125590 [TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine. Mehta J; Powles R; Treleaven J; Horton C; Tait D; Meller S; Pinkerton CR; Middleton G; Eisen T; Singhal S Bone Marrow Transplant; 1996 Oct; 18(4):741-6. PubMed ID: 8899189 [TBL] [Abstract][Full Text] [Related]
12. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation. Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710 [TBL] [Abstract][Full Text] [Related]
13. The impact of cyclosporin A on acute graft-versus-host disease after allogeneic bone marrow transplantation in children and adolescents with acute lymphoblastic leukemia. Teuffel O; Schrauder A; Sykora KW; Zimmermann M; Reiter A; Welte K; Schrappe M Bone Marrow Transplant; 2005 Jul; 36(2):145-50. PubMed ID: 15908976 [TBL] [Abstract][Full Text] [Related]
14. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis. Byrne JL; Stainer C; Hyde H; Miflin G; Haynes AP; Bessell EM; Russell NH Bone Marrow Transplant; 1998 Sep; 22(6):541-5. PubMed ID: 9758340 [TBL] [Abstract][Full Text] [Related]
15. Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. Chao NJ; Snyder DS; Jain M; Wong RM; Niland JC; Negrin RS; Long GD; Hu WW; Stockerl-Goldstein KE; Johnston LJ; Amylon MD; Tierney DK; O'Donnell MR; Nademanee AP; Parker P; Stein A; Molina A; Fung H; Kashyap A; Kohler S; Spielberger R; Krishnan A; Rodriguez R; Forman SJ; Bluzme KG Biol Blood Marrow Transplant; 2000; 6(3):254-61. PubMed ID: 10871150 [TBL] [Abstract][Full Text] [Related]
16. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Bacigalupo A; Lamparelli T; Barisione G; Bruzzi P; Guidi S; Alessandrino PE; di Bartolomeo P; Oneto R; Bruno B; Sacchi N; van Lint MT; Bosi A; Biol Blood Marrow Transplant; 2006 May; 12(5):560-5. PubMed ID: 16635791 [TBL] [Abstract][Full Text] [Related]
17. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Van Lint MT; Uderzo C; Locasciulli A; Majolino I; Scimé R; Locatelli F; Giorgiani G; Arcese W; Iori AP; Falda M; Bosi A; Miniero R; Alessandrino P; Dini G; Rotoli B; Bacigalupo A Blood; 1998 Oct; 92(7):2288-93. PubMed ID: 9746766 [TBL] [Abstract][Full Text] [Related]
18. G-CSF-primed haploidentical marrow transplantation without ex vivo T cell depletion: an excellent alternative for high-risk leukemia. Ji SQ; Chen HR; Wang HX; Yan HM; Zhu L; Liu J; Xue M; Xun CQ Bone Marrow Transplant; 2002 Dec; 30(12):861-6. PubMed ID: 12476277 [TBL] [Abstract][Full Text] [Related]
19. Hyperkalemia associated with cyclosporine (CsA) use in bone marrow transplantation. Fleming DR; Ouseph R; Herrington J Bone Marrow Transplant; 1997 Feb; 19(3):289-91. PubMed ID: 9028560 [TBL] [Abstract][Full Text] [Related]
20. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies. Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S Clin Transpl; 1996; ():281-90. PubMed ID: 9286578 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]